CareDx Future Growth
Future criteria checks 3/6
CareDx is forecast to grow earnings and revenue by 98% and 7.6% per annum respectively while EPS is expected to grow by 98.2% per annum.
Key information
98.0%
Earnings growth rate
98.23%
EPS growth rate
| Biotechs earnings growth | 23.4% |
| Revenue growth rate | 7.6% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 30 Apr 2026 |
Recent future growth updates
Recent updates
CDNA: Wider 2026 Revenue Outlook And CMS Overhang Will Drive Repricing
Analysts have raised their average price target on CareDx by $1 to $26 per share, citing a solid Q4, a wide but above-consensus 2026 revenue outlook, and a view that the stock still appears inexpensive even with ongoing uncertainty around the CMS outcome. Analyst Commentary Recent Street commentary highlights a mix of optimism around CareDx's execution and revenue outlook, alongside ongoing caution tied to policy risk.CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results
Apr 18CDNA: Wider 2026 Guide And CMS Overhang Will Drive Repricing
Analysts have lifted their price target on CareDx by $1 to $26, citing a solid Q4, a 2026 revenue outlook set above Street estimates, and a view that shares look inexpensive even with ongoing CMS uncertainty. Analyst Commentary Street research points to a mixed but generally constructive view on CareDx, with analysts weighing a solid recent quarter and new long term revenue guidance against ongoing policy risks and execution questions.
CDNA: Final MolDX LCD Decision Will Drive 2026 Outlook And Upside Potential
Narrative Update on CareDx Analysts have raised their implied fair value estimate for CareDx to $21.00 from $20.00. This reflects updated views on 2026 revenue guidance, reimbursement uncertainty and the stock's valuation relative to recent Street research commentary.CDNA: Wider 2026 Outlook And CMS LCD Overhang Will Drive Repricing
The analyst price target for CareDx has shifted from $23 to $24.80, as analysts balance a wider 2026 revenue outlook and recent Q4 performance against ongoing uncertainty around the final CMS LCD and its impact on long term growth. Analyst Commentary Recent Street commentary reflects a split view on CareDx, with some analysts focusing on upside tied to execution and valuation, while others emphasize uncertainty around reimbursement and longer term growth.CDNA: Final MolDX LCD Outcome Will Shape Appeal Despite 2026 Guidance
The analyst price target for CareDx has been raised from $18 to $20. Analysts point to a higher assumed revenue growth outlook, a slightly higher future P/E, and management's 2026 revenue guidance, while still flagging uncertainty around the final CMS LCD and its impact on longer term growth and volumes.CDNA: MolDX LCD Outcome Will Temper Appeal Despite Solid 2025 Guidance
Analysts have lowered their outlook on CareDx, reducing the price target to $26. They see a less compelling risk reward profile given uncertainty around the final MolDX LCD and how it could affect 2026 revenue, longer term growth, and near term test volumes.
CDNA: Reimbursement Outcomes Will Drive Future Upside Despite Cautious Rating
Analysts have trimmed their fair value estimate for CareDx from US$28 to US$26, citing a less compelling risk reward outlook as revenue and longer term growth now appear more closely tied to uncertain reimbursement outcomes and a much higher assumed future P/E. Analyst Commentary Recent research points to a more cautious stance on CareDx, with the key concern being how much future revenue and growth now hinge on reimbursement decisions and a higher assumed future P/E multiple.CDNA: MolDX LCD Uncertainty Will Restrain Appeal Despite Raised Guidance
Narrative Update on CareDx The analyst price target for CareDx has been reset to US$18.00. This reflects what analysts see as a less compelling risk reward profile, given uncertainty around future revenue tied to the final MolDX LCD and the possibility that upcoming estimates and longer term growth expectations may be too optimistic.CDNA: Raised Guidance And Share Buyback Will Shape Balanced Outlook
Analysts have raised their price target on CareDx from 14 dollars to 18 dollars, citing expectations for stronger revenue growth and a higher future earnings multiple, despite a modestly higher discount rate and lower projected profit margins. What's in the News Shareholder derivative lawsuits against current and former directors are moving toward a proposed global settlement, with a final approval hearing scheduled for June 30, 2026 in the U.S. District Court for the Northern District of California (shareholder litigation notice).CDNA: Raised Revenue Outlook And Buyback Activity Will Support Bullish Repricing
Analysts have nudged their price target on CareDx higher from around 21.83 dollars to 23.00 dollars, citing expectations for slightly faster revenue growth and a richer future valuation multiple, despite a more conservative view on long term profit margins and discount rates. What's in the News The board amended and restated company bylaws to adopt a majority voting standard for director elections, with plurality voting only in contested elections (company bylaws filing).CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 25% But Its Business Still Trails The Industry
Nov 29
We Believe CareDx's (NASDAQ:CDNA) Earnings Are A Poor Guide For Its Profitability
Nov 12CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Sep 19Calculating The Intrinsic Value Of CareDx, Inc (NASDAQ:CDNA)
Aug 27Rising Organ Transplant Needs Will Reshape Diagnostics Despite Challenges
CareDx’s consensus price target was reduced from $27.50 to $22.20, primarily due to heightened reimbursement risk stemming from the proposed Palmetto MolDx LCD and recent share price volatility, despite operational stability and some analysts seeing undervaluation at current levels. Analyst Commentary Ongoing uncertainty surrounding the Palmetto MolDx draft Local Coverage Determination (LCD), which proposes to limit reimbursement for certain transplant tests.The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 32%
Jul 23Is There An Opportunity With CareDx, Inc's (NASDAQ:CDNA) 28% Undervaluation?
May 02
AlloMap Testing And OPTN Project Will Expand Markets Despite Risks
CareDx's growth fueled by expanded testing services and strategic investments aims to improve margins and revenue cycle management.CareDx: Some Litigation Clouds Have Cleared
Mar 13Why CareDx's (NASDAQ:CDNA) Earnings Are Weaker Than They Seem
Mar 11CareDx: Too Risky For Me
Dec 30The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
Nov 05CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Sep 29CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Aug 01CareDx: Benefiting From Some Certainty
Jul 15Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
Apr 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 507 | 49 | N/A | N/A | 2 |
| 12/31/2027 | 481 | 18 | N/A | 77 | 7 |
| 12/31/2026 | 456 | 1 | N/A | 48 | 7 |
| 3/31/2026 | 413 | -8 | 64 | 73 | N/A |
| 12/31/2025 | 380 | -21 | 35 | 42 | N/A |
| 9/30/2025 | 358 | 70 | 36 | 43 | N/A |
| 6/30/2025 | 341 | 58 | 12 | 18 | N/A |
| 3/31/2025 | 346 | 62 | 20 | 27 | N/A |
| 12/31/2024 | 334 | 53 | 32 | 38 | N/A |
| 9/30/2024 | 313 | -153 | 1 | 8 | N/A |
| 6/30/2024 | 297 | -166 | -22 | -15 | N/A |
| 3/31/2024 | 275 | -186 | -42 | -34 | N/A |
| 12/31/2023 | 280 | -190 | -28 | -18 | N/A |
| 9/30/2023 | 297 | -91 | -14 | -3 | N/A |
| 6/30/2023 | 309 | -84 | -14 | 0 | N/A |
| 3/31/2023 | 320 | -81 | -22 | -3 | N/A |
| 12/31/2022 | 322 | -77 | -50 | -25 | N/A |
| 9/30/2022 | 319 | -74 | -55 | -28 | N/A |
| 6/30/2022 | 315 | -69 | -45 | -21 | N/A |
| 3/31/2022 | 308 | -50 | -34 | -7 | N/A |
| 12/31/2021 | 296 | -31 | -40 | -19 | N/A |
| 9/30/2021 | 276 | -18 | -31 | -16 | N/A |
| 6/30/2021 | 254 | -9 | -27 | -11 | N/A |
| 3/31/2021 | 221 | -14 | -8 | 3 | N/A |
| 12/31/2020 | 192 | -19 | 23 | 33 | N/A |
| 9/30/2020 | 169 | -20 | 14 | 25 | N/A |
| 6/30/2020 | 150 | -19 | 13 | 21 | N/A |
| 3/31/2020 | 139 | -20 | -4 | 0 | N/A |
| 12/31/2019 | 127 | -22 | N/A | -3 | N/A |
| 9/30/2019 | 115 | -21 | N/A | 0 | N/A |
| 6/30/2019 | 102 | -39 | N/A | 0 | N/A |
| 3/31/2019 | 88 | -45 | N/A | -5 | N/A |
| 12/31/2018 | 77 | -47 | N/A | -4 | N/A |
| 9/30/2018 | 66 | -75 | N/A | -8 | N/A |
| 6/30/2018 | 57 | -69 | N/A | -11 | N/A |
| 3/31/2018 | 51 | -59 | N/A | -12 | N/A |
| 12/31/2017 | 48 | -55 | N/A | -14 | N/A |
| 9/30/2017 | 47 | -39 | N/A | -15 | N/A |
| 6/30/2017 | 47 | -29 | N/A | -14 | N/A |
| 3/31/2017 | 46 | -35 | N/A | -17 | N/A |
| 12/31/2016 | 41 | -39 | N/A | -17 | N/A |
| 9/30/2016 | 36 | -29 | N/A | -17 | N/A |
| 6/30/2016 | 31 | -28 | N/A | -19 | N/A |
| 3/31/2016 | 27 | -21 | N/A | -15 | N/A |
| 12/31/2015 | 28 | -14 | N/A | -10 | N/A |
| 9/30/2015 | 29 | -9 | N/A | -6 | N/A |
| 6/30/2015 | 29 | -4 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDNA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.4%).
Earnings vs Market: CDNA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CDNA is expected to become profitable in the next 3 years.
Revenue vs Market: CDNA's revenue (7.6% per year) is forecast to grow slower than the US market (11.1% per year).
High Growth Revenue: CDNA's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDNA's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 06:41 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CareDx, Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |